Anthem Biosciences Ltd
Incorporated in 2006, Anthem Biosciences
Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients.[1]
- Market Cap ₹ 44,419 Cr.
- Current Price ₹ 789
- High / Low ₹ 874 / 579
- Stock P/E 64.6
- Book Value ₹ 56.7
- Dividend Yield 0.25 %
- ROCE 32.1 %
- ROE 24.3 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 20.4% CAGR over last 5 years
Cons
- Stock is trading at 13.9 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 626 | 633 | 1,103 | 1,231 | 1,057 | 1,418 | 1,841 | 2,089 | |
| 454 | 451 | 695 | 666 | 626 | 912 | 1,151 | 1,238 | |
| Operating Profit | 172 | 182 | 408 | 566 | 431 | 505 | 690 | 851 |
| OPM % | 27% | 29% | 37% | 46% | 41% | 36% | 37% | 41% |
| 21 | 21 | 37 | 49 | 139 | 70 | 109 | 158 | |
| Interest | 18 | 20 | 17 | 10 | 9 | 9 | 9 | 7 |
| Depreciation | 61 | 62 | 62 | 58 | 64 | 81 | 78 | 100 |
| Profit before tax | 114 | 121 | 366 | 547 | 498 | 485 | 711 | 903 |
| Tax % | 32% | 23% | 26% | 26% | 23% | 23% | 29% | 26% |
| 77 | 93 | 271 | 406 | 386 | 375 | 506 | 671 | |
| EPS in Rs | 91.97 | 110.62 | 319.77 | 462.60 | 6.76 | 6.70 | 9.05 | 11.94 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 17% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 26% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 20% |
| 3 Years: | 26% |
| TTM: | 36% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 25% |
| 3 Years: | 23% |
| Last Year: | 24% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 9 | 114 | 112 | 112 | 112 |
| Reserves | 323 | 413 | 693 | 1,347 | 1,628 | 1,821 | 2,361 | 3,072 |
| 192 | 159 | 100 | 35 | 115 | 173 | 113 | 50 | |
| 194 | 207 | 232 | 228 | 136 | 219 | 249 | 296 | |
| Total Liabilities | 718 | 787 | 1,034 | 1,619 | 1,993 | 2,324 | 2,836 | 3,531 |
| 316 | 306 | 361 | 329 | 449 | 478 | 624 | 613 | |
| CWIP | 12 | 50 | 19 | 153 | 143 | 156 | 58 | 84 |
| Investments | 73 | 99 | 209 | 273 | 499 | 472 | 533 | 1,380 |
| 318 | 333 | 444 | 865 | 902 | 1,219 | 1,620 | 1,455 | |
| Total Assets | 718 | 787 | 1,034 | 1,619 | 1,993 | 2,324 | 2,836 | 3,531 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 196 | 166 | 278 | 333 | 319 | 164 | 440 | 889 | |
| -121 | -109 | -196 | -206 | -378 | -192 | -246 | -742 | |
| -65 | -48 | -63 | 181 | 53 | -132 | -66 | -44 | |
| Net Cash Flow | 9 | 9 | 18 | 308 | -6 | -159 | 127 | 104 |
| Free Cash Flow | 144 | 119 | 159 | 308 | 145 | 41 | 313 | 753 |
| CFO/OP | 114% | 116% | 85% | 81% | 101% | 56% | 87% | 128% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 61 | 84 | 97 | 95 | 126 | 89 | 100 |
| Inventory Days | 123 | 186 | 29 | 52 | 139 | 129 | 167 | 55 |
| Days Payable | 72 | 87 | 50 | 58 | 77 | 61 | 54 | 32 |
| Cash Conversion Cycle | 119 | 160 | 63 | 91 | 157 | 194 | 201 | 122 |
| Working Capital Days | 22 | 20 | 27 | 75 | 114 | 129 | 128 | 198 |
| ROCE % | 26% | 55% | 51% | 28% | 25% | 31% | 32% |
Insights
In beta| Mar 2010 | Mar 2012 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Custom Synthesis Capacity kL |
|
|||||||||||
| Fermentation Capacity kL |
||||||||||||
| Fixed Asset Turnover x |
||||||||||||
| Number of Employees Number |
||||||||||||
| Scientific Staff Number |
||||||||||||
| Number of Commercial Molecules Number |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
5 Jun - Schedule of Institutional Call to be held on June 10, 2026
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
22 May - Management to attend Nomura Investment Forum Asia 2026 and Citi India Conference 2026 on 2-5 June.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
22 May - Earnings Call transcript for Earnings Call held on May 20, 2026, for the Audited Standalone and Consolidated financial results for the quarter and year ended …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
20 May - Audio recording of FY26 earnings call for quarter and year ended March 31, 2026 made available online.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
20 May - Newspaper Publication for Audited Financial Results of the Company for the quarter and year ended March 31, 2026
Concalls
-
May 2026Transcript PPT REC
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT REC
Business Overview:[1]
ABL is a Contract Research, Development,
and Manufacturing Organization with fully integrated operations across the drug discovery, development, and manufacturing value chain. It is among the few companies in India offering capabilities in both New Chemical
Entity (NCE) and New Biological Entity (NBE) programs. The company has developed various platforms such as RNA interference (RNAi),
Antibody-Drug Conjugates (ADCs), peptides, lipids, and oligonucleotides.